We observed that patients with IDH1-R132H positive astrocytic tumors had a longer progressive-free survival (PFS) than those with IDH1- R132H negative astrocytic tumors (Figure 3A; Median PFS of IDH1-R132H positive=802 days, Median PFS of IDH1-R132H negative=461.5 days; p<0.0001). This evidence concerns the gene IDH1 and astrocytic tumor.